Pulmonx Corporation (LUNG)
| Market Cap | 83.63M +24.4% |
| Revenue (ttm) | 87.44M -3.4% |
| Net Income | -48.12M |
| EPS | -1.15 |
| Shares Out | 42.24M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 558,306 |
| Open | 2.020 |
| Previous Close | 2.060 |
| Day's Range | 1.870 - 2.030 |
| 52-Week Range | 1.130 - 2.890 |
| Beta | 0.28 |
| Analysts | Buy |
| Price Target | 3.40 (+71.72%) |
| Earnings Date | Jul 29, 2026 |
About LUNG
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with mult... [Read more]
Financial Performance
In 2025, Pulmonx's revenue was $90.50 million, an increase of 8.01% compared to the previous year's $83.79 million. Losses were -$54.00 million, -4.24% less than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for LUNG stock is "Buy." The 12-month stock price target is $3.4, which is an increase of 71.72% from the latest price.
News
Pulmonx reports Q2 EPS (24c), consensus (28c)
Reports Q2 revenue $22.75M, consensus $22.39M. “We are pleased with the progress we made in the second quarter executing our commercial strategy, advancing our clinical initiatives, and beginning to d...
Pulmonx backs FY26 revenue view $90M-$92M, consensus $90.77M
The company said, “Pulmonx (LUNG) continues to expect revenue for the full year 2026 to be in the range of $90 million to $92 million. The Company now expects gross…
Pulmonx Earnings Call Transcript: Q2 2026
Q2 2026 revenue reached $22.8M, with net loss and adjusted EBITDA loss both significantly reduced year-over-year. Gross margin improved to 78%, and cost alignment initiatives drove a 16% decrease in operating expenses. Full-year guidance is reaffirmed, with China shipments set to resume in early 2027.
Pulmonx Earnings release: Q2 2026
Pulmonx released its Q2 2026 earnings on July 29, 2026, summarizing the period's financial results.
Pulmonx Quarterly report: Q2 2026
Pulmonx has published its Q2 2026 quarterly earnings report on July 29, 2026.
Pulmonx Reports Second Quarter 2026 Financial Results
REDWOOD CITY, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today report...
Pulmonx to Present at the Canaccord Genuity 46th Annual Growth Conference
REDWOOD CITY, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the com...
Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026
REDWOOD CITY, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will ...
Pulmonx Transcript: AGM 2026
The meeting covered board introductions, voting on director elections, auditor ratification, and executive compensation, with all proposals approved. No shareholder questions were raised, and voting results will be filed with the SEC.
Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announ...
Pulmonx Transcript: Bank of America Global Healthcare Conference 2026
A minimally invasive valve system for severe emphysema has shown strong clinical results and high reimbursement rates, with global reach and a $12 billion addressable market. Recent pipeline expansion and financial restructuring aim to drive renewed growth.
Pulmonx reports Q1 EPS (33c), consensus (33c)
Reports Q1 revenue $20.59M, consensus $20.43M. “During the first quarter we initiated our refreshed U.S. commercial strategies and continued to execute in our direct international markets. We are enco...
Pulmonx backs FY26 revenue view $90M-$92M, consensus $90.87M
The company said, “Pulmonx (LUNG) continues to expect revenue for the full year 2026 to be in the range of $90 million to $92 million. The Company continues to expect…
Pulmonx Earnings Call Transcript: Q1 2026
Q1 2026 revenue declined 9% year-over-year to $20.6 million, with U.S. and international sales both down due to China registration delays, but excluding China, international markets grew 22%. Cost reductions, a new credit facility, and a focused sales strategy support reaffirmed 2026 guidance and expectations for double-digit growth exiting the year.
Pulmonx Earnings release: Q1 2026
Pulmonx released its Q1 2026 earnings on April 29, 2026, summarizing the period's financial results.
Pulmonx Quarterly report: Q1 2026
Pulmonx has published its Q1 2026 quarterly earnings report on April 29, 2026.
Pulmonx Reports First Quarter 2026 Financial Results
REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today repor...
Pulmonx to Present at the Bank of America Securities 2026 Health Care Conference
REDWOOD CITY, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the co...
Pulmonx Proxy statement: Proxy filing
Pulmonx filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
Pulmonx Proxy statement: Proxy filing
Pulmonx filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
Pulmonx to Report First Quarter 2026 Financial Results on April 29, 2026
REDWOOD CITY, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will...
Pulmonx price target lowered to $5 from $6 at Canaccord
Canaccord analyst William Plovanic lowered the firm’s price target on Pulmonx (LUNG) to $5 from $6 and keeps a Buy rating on the shares. The firm said Q4 results came…
Pulmonx reports Q4 EPS (25c), consensus (38c)
Reports Q4 revenue $22.6M, consensus $21.73M. “While our recent performance reflects a period of transition, we see a substantial opportunity to rebuild momentum through a clear operating plan focused...
Pulmonx sees FY26 revenue $90M-$92M, consensus $94.23M
The company said, “Pulmonx (LUNG) expects revenue for the full year 2026 to be in the range of $90 million to $92 million. The Company expects gross margin for the…
Pulmonx Earnings Call Transcript: Q4 2025
Revenue grew 8% in 2025 to $90.5M, with international strength offsetting U.S. challenges. Cost restructuring and a new $60M credit facility improved financial flexibility. 2026 guidance anticipates resumed growth in H2, improved margins, and reduced cash burn.